National pharmaceutical companies will invest 10 billion pesos, including the first plasma fractionation plant.

CDMX .- President Claudia Sheinbaum Pardo announced the investment within the next few years of four national pharmaceutical companies , which together add up to more than 10.48 billion pesos as part of the Mexico Plan .

Mexican companies that have decided to join Plan Mexico and that have very important investment plans, some of which will yield results very soon," he said at the start of his morning press conference.

Federico Prince Laris , CEO and general manager of Laboratorios Kener , announced that he will invest 5.18 billion pesos in the country to expand the country's manufacturing capacity with a medical supplies plant.

The goal is to create 800 direct jobs and 2,000 indirect jobs with an injectable plant , a mixing center , comprehensive anesthesia services , Car-T Cell production , and new health registrations .

"Today we proudly announce an investment plan of more than 5.18 billion pesos, which includes the expansion of our plant to triple our installed capacity, with opening scheduled for the first quarter of 2027. This will allow us to guarantee national pharmaceutical sovereignty for several of our products, as well as the creation of a mixing center for oncology, antibiotics, and parenteral nutrition," he stated.

He also invited President Claudia Sheinbaum Pardo to attend the event in February 2027 to inaugurate the country's most modern and productive sterile injectable drug plant, a world-class facility, "a symbol of the national industry's commitment to health, innovation, and the future of Mexico."

Meanwhile, the general director of GENBIO , José Miguel Ramos Rodríguez , announced an investment of 4 billion pesos, 2.4 billion pesos initially, and subsequently 1.6 billion pesos, for the installation and operation of the first plasma fractionation plant in Latin America for the production of albumin, immunoglobulins and coagulation factors, putting an end to more than 20 years of dependence on imported products.

100 specialized jobs will be created in biotechnology, engineering, and pharmaceutical processes.

Luz Astrea Ocampo Gutiérrez de Velasco , CEO of Grupo Neolpharma , detailed the 800 million peso investment in infrastructure construction and the development of biopharmaceuticals, biotechnological medicines, and vaccines. This will improve access to highly specialized treatments, foster innovation, and promote economic growth.

Infrastructure construction and development of biopharmaceuticals, biotechnological medicines, and vaccines. This will improve access to highly specialized treatments, foster innovation, and promote economic growth.

Meanwhile, Diego Antonio Gutiérrez de Velasco , Executive Chairman of the Board of Neolsym Group, announced an investment of 800 million pesos in infrastructure for the domestic production of active pharmaceutical ingredients (APIs), improving access to medicines and health security. Innovative, more environmentally friendly processes and new molecules are being implemented. Marketing for the domestic and export markets.

A.M

Written in Economics on 3/7/2025 · 1:45 PM

El Universal, with more than 100 years of history, is among the most prestigious newspapers in Latin America.